RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
Business
•
March 6, 2026
•
0 Views
Source: https://finance.yahoo.com/rss/topstories - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!
